Date: 2017-05-04
Type of information: Nomination
Compound: president and chief executive officer
Company: Swedish Orphan Biovitrum - SOBI (Sweden)
Therapeutic area: Rare diseases - Genetic diseases - Hematological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On May 4, 2017, Swedish Orphan Biovitrum (Sobi™) announced that Guido Oelkers has been appointed President and Chief Executive Officer effective as of 22 May 2017, succeeding Geoffrey McDonough. Guido Oelkers joins Sobi from his previous role as CEO at BSN Medical GmbH. He has extensive experience from pharmaceutical and health care companies including a role as President and CEO of the Swedish medtech company Gambro, CEO of the specialty pharmaceutical company Invida and a number of executive commercial operations roles in companies such as Nycomed, DKSH Group and Aventis (formerly Hoechst), where he began his career. Guido Oelkers was also a member of the Board of Directors for Meda.
- Guido Oelkers was born in 1965 and holds a PhD in Strategic Management from the University of South Australia and a Master of Economics from South Bank University, London. He complemented his postgraduate studies in Economics at London School of Economics and Political Science. Guido Oelkers is going to relocate to Stockholm, Sweden.
----
Financial terms:
Latest news:
Is general: Yes
